MATCHING ADJUSTED INDIRECT COMPARISON OF FILGOTINIB VS. TOFACITINIB IN MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

被引：0
|
作者：
Gharaibeh, M. [1 ]
Smith, N. [2 ]
Jeyakumar, S. [2 ]
Mark, E. [1 ]
Shreay, S. [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[2] Maple Hlth Grp LLC, New York, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.6108
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0142
引用
收藏
页码：1005 / 1006
页数：2
相关论文
共 50 条
  • [1] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Edwards, Christopher J.
    Sawant, Ruta
    Garg, Vishvas
    Du, Ella X.
    Friedman, Alan
    Betts, Keith A.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 167 - 181
  • [2] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Christopher J. Edwards
    Ruta Sawant
    Vishvas Garg
    Ella X. Du
    Alan Friedman
    Keith A. Betts
    Rheumatology and Therapy, 2021, 8 : 167 - 181
  • [3] MATCHING-ADJUSTED INDIRECT COMPARISON OF IXEKIZUMAB VS. TOFACITINIB IN PSORIATIC ARTHRITIS
    Sapin, C.
    Panni, T.
    Meszaros, G.
    Hill, J.
    Hartz, S.
    VALUE IN HEALTH, 2020, 23 : S593 - S593
  • [4] The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
    Weinblatt, Michael E.
    Mease, Philip
    Mysler, Eduardo
    Takeuchi, Tsutomu
    Drescher, Edit
    Berman, Alberto
    Xing, Jun
    Zilberstein, Moshe
    Banerjee, Subhashis
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (10) : 2591 - 2600
  • [5] Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
    Kivitz, A. J.
    Gutierrez-Urena, S. R.
    Poiley, J.
    Genovese, M. C.
    Kristy, R.
    Shay, K.
    Wang, X.
    Garg, J. P.
    Zubrzycka-Sienkiewicz, A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (04) : 709 - 719
  • [6] Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
    Buch, Maya H.
    Walker, David
    Edwards, Christopher J.
    Barry, Jane
    Akroyd, Laura
    Omoruyi, Edmund V. Ekoka
    Taylor, Peter C.
    RHEUMATOLOGY, 2024,
  • [7] Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
    Warren, R. B.
    Brnabic, A.
    Saure, D.
    Langley, R. G.
    See, K.
    Wu, J. J.
    Schacht, A.
    Mallbris, L.
    Nast, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1064 - 1071
  • [8] Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China
    Xu, Xinyi
    Geng, Linyu
    Xu, Xue
    Huang, Saisai
    Liang, Jun
    IMMUNOTHERAPY, 2024,
  • [9] A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF UPADACITINIB VERSUS TOFACITINIB IN CSDMARD-IR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA)
    Edwards, Christopher
    Sawant, Ruta
    Du, Ella
    Cammarota, Jordan
    Tang, Patrick
    Garg, Vishvas
    Friedman, Alan
    Betts, Keith
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 358 - 358
  • [10] FEASIBILITY OF MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF OMALIZUMAB (OMA) VS. MEPOLIZUMAB (MEPO) IN MODERATE-TO-SEVERE ASTHMA
    Ayyagari, R.
    Alvares, L.
    Mu, F.
    Hacking, V
    Martinez, R.
    Signorovitch, J. E.
    VALUE IN HEALTH, 2016, 19 (07) : A549 - A549
12345